Get the latest news, insights, and market updates on VTRS (Viatris Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 20 Feb 3, 2026 - $VTRS
Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch
Viatris (VTRS) is back in focus after the company launched its heart failure treatment Inpefa in the United Arab Emirates, marking its first commercialization of the drug outside the U.S. and Europe. See our latest analysis for Viatris. The Inpefa launch lands at a time when momentum in Viatris' share price has been building, with a 30 day share price return of 7.92% and a 90 day share price return of 27.63%. The 1 year total shareholder return sits at 23.94%, compared with a weaker 5 year... Jan 24, 2026 - $VTRS
Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery
If you are wondering whether Viatris might still offer value at its current share price, this article walks through what the numbers are really saying about the stock. The shares recently closed at US$13.21, with returns of 2.7% over 7 days, 7.9% over 30 days, 6.0% year to date, 23.9% over 1 year and 27.5% over 3 years, while the 5 year return sits at a 4.9% decline. Recent news coverage has focused on Viatris as a large U.S. listed pharmaceuticals and biotech company. This keeps investor... Jan 24, 2026 - $VTRS
3 Reasons to Sell VTRS and 1 Stock to Buy Instead
What a time it’s been for Viatris. In the past six months alone, the company’s stock price has increased by a massive 41.5%, reaching $13.07 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Jan 22, 2026 - $VTRS
3 Cash-Producing Stocks with Questionable Fundamentals
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning. Jan 16, 2026 - $VTRS
3 Volatile Stocks We Keep Off Our Radar
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. Jan 15, 2026 - $VTRS
Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target
The recent update to Viatris centers on a refreshed US$16 price target, set against a fair value estimate that has inched from about US$12.44 to roughly US$12.67 as the affordable medicines theme gains attention. Analysts tying the higher target to this theme are effectively saying the model now gives slightly more credit to Viatris’ ability to fit ongoing demand for cost conscious healthcare options as 2026 approaches. Continue reading this article to see how you can keep on top of these... Jan 9, 2026 - $VTRS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple